Avio Smart Market Stack Limited, formerly known as Bartronics India Limited, has initiated an expanded collaboration with Huwel Lifesciences to introduce a range of patented molecular diagnostic products across multiple healthcare segments in India.
The development follows the recently signed Shareholders’ Agreement between the two companies, under which they aim to jointly scale advanced diagnostic technologies and introduce Molecular Diagnostic Products to institutional and healthcare markets across the country.
Expanding Pipeline of Molecular Diagnostic Technologies
Huwel Lifesciences has developed multiple patented diagnostic technologies and is building a strong pipeline of new products, with several additional patents and platforms currently under development.
The company’s capabilities span RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels, forming the foundation of its expanding portfolio of Molecular Diagnostic Products.
Also Read: Ayukriyam Innovations Secures TDB Support for AI-Driven Autoscope Diagnostic Platform
Research, assay development, and manufacturing activities are conducted within Huwel’s own facilities. This vertically integrated approach allows the company to design, develop, and manufacture key components of its Molecular Diagnostic Products ecosystem internally.
Positioning itself as a fully indigenous diagnostics innovator, Huwel Lifesciences is among the few molecular diagnostics companies in India capable of developing most elements of its diagnostic platforms in-house.
This approach aligns with the Government of India’s Make in India initiative and aims to strengthen the domestic ecosystem for Molecular Diagnostic Products and healthcare technologies.
Large Market Opportunity for Molecular Diagnostic Products in India
India represents one of the largest global markets for infectious disease diagnostics. National health programs and institutional healthcare networks together conduct tens of millions of diagnostic tests annually for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions.
The diagnostics market for these diseases alone is estimated to exceed ₹5,000 crore annually in India, creating significant opportunities for the deployment of innovative Molecular Diagnostic Products that can support faster detection and large-scale disease surveillance.
Huwel’s molecular diagnostic solutions are designed to enable rapid and cost-efficient tuberculosis detection using open RT-PCR systems, allowing tests to run on RT-PCR laboratory infrastructure that was widely deployed across the country during the COVID-19 pandemic.
This approach allows public health systems to adopt new Molecular Diagnostic Products without requiring significant new infrastructure investments.
Expanding Disease Detection Platforms
The company’s tuberculosis molecular diagnostic platform has already received the necessary regulatory approvals and validations. Building on the same technology platform, Huwel Lifesciences has also developed Molecular Diagnostic Products for multiple disease segments.
These include molecular diagnostics for HIV, HPV-based cervical cancer screening, antimicrobial resistance (AMR) surveillance, hepatitis, and several other infectious diseases.
The solutions are designed to operate on scalable open RT-PCR systems that are suitable for large-scale testing programs and institutional healthcare networks.
Also Read: Prantae Solutions Receives TDB Support for Point-of-Care Kidney Diagnostic Technology Proflo-U
Commercialization Strategy for Molecular Diagnostic Products
As part of the collaboration, Avio Smart Market Stack Limited (ASMS) will support the go-to-market strategy, institutional engagement, and commercialization of these Molecular Diagnostic Products.
The company plans to leverage its institutional relationships, digital infrastructure capabilities, and experience in executing large-scale programs.
Commenting on the collaboration, Vidhyasagar Reddy, Managing Director, Avio Smart Market Stack Limited, said: “India has a significant opportunity to strengthen its public health infrastructure through indigenous diagnostic innovation. Our collaboration with Huwel Lifesciences brings together advanced molecular diagnostic technologies and our institutional market access capabilities.
By leveraging the extensive RT-PCR infrastructure established across the country during the pandemic, we aim to accelerate the availability of rapid, accurate, and affordable diagnostics for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions. This partnership aligns with our broader vision of supporting scalable health-tech solutions that can improve healthcare access across India.”
Scaling Indigenous Molecular Diagnostic Products
Over the coming years, Avio Smart Market Stack Limited and Huwel Lifesciences expect to introduce multiple diagnostic product lines across different disease segments.
The companies aim to expand the availability of indigenous Molecular Diagnostic Products across government health programs, hospital networks, diagnostic laboratories, and private healthcare providers.
